TTTomo Takenaga

Tomo Takenaga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomo Takenaga has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Haruhiro Kondo

    Department of Obstetrics and Gynecology St. Marianna University School of Medicine Kawasaki Japan

    1 shared publication
  • Haruka Imai

    Department of Obstetrics and Gynecology St. Marianna University School of Medicine Kawasaki Japan

    1 shared publication
  • Jun Takeuchi

    Department of Obstetrics and Gynecology St. Marianna University School of Medicine Kawasaki Japan

    1 shared publication
  • Kenichiro Tanabe

    Department of Frontier Medicine, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan

    1 shared publication
  • Nao Suzuki

    Department of Obstetrics and Gynecology, St. Marianna Medical University School of Medicine, Kawasaki, Japan

    1 shared publication
  • Ryo Kanamori

    Department of Obstetrics and Gynecology St. Marianna University School of Medicine Kawasaki Japan

    1 shared publication

Latest Publications

  • Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy

    by Tomo Takenaga, Shiho Kuji, Ken‐Ichiro Tanabe, Ryo Kanamori, Haruka Imai, Jun Takeuchi, Haruhiro Kondo, Tatsuru Ohara, Tsuguo Iwatani, Nao Suzuki

    Objective: Gynecologic cancer chemotherapy impacts the quality of life (QOL) of patients, with lasting adverse events that may require treatment adjustments or discontinuation. Consequently, real‐time symptom monitoring before outpatient visits has resulted in improved QOL for patients and extended survival times. This study investigated whether there are differences between electronic patient‐reported outcomes (e‐PRO‐CTCAE) and physician‐assessed outcomes (NCI‐CTCAE) evaluated in an outpatient setting in gynecologic cancer chemotherapy.Methods: The study was conducted on 50 patients who received their first chemotherapy treatment at St. Marianna University Hospital Obstetrics and Gynecology from July 1, 2021 to December 31, 2022. PRO‐CTCAE and NCI‐CTCAE were evaluated at each instance of chemotherapy and 2 weeks after. The PRO‐CTCAE was additionally collected weekly using e‐PRO.Results: The values for “Joint Pain,” “Nausea,” “Taste Disturbance,” “Constipation,” “Insomnia,” “Fatigue,” “Limb Edema,” and “Concentration Impairment” were consistently higher in PRO‐CTCAE than in NCI‐CTCAE, indicating that physicians underestimated the severity of adverse events. In contrast, there was no significant difference in “Peripheral Neuropathy,” demonstrating that physicians had a good understanding of this condition in patients. The weekly responses obtained from e‐PRO revealed that symptom exacerbations peaked outside of clinic visits.Conclusions: This study demonstrated physicians tend to underestimate most adverse events. Moreover, the responses using e‐PRO revealed peak symptom deterioration occurred outside of outpatient visits. This suggested that e‐PRO and actions taken in response to them can improve patients' QOL.